Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: Programmed Cell Death 1 Ligand 2

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.

The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).

Study Keyword: Programmed Cell Death 1 Ligand 2

Study of Pembrolizumab Versus Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma

May 20, 2022

By Tyler Kalist

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient

A Study of Belzutifan Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy

May 20, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of

Pembrolizumab as First-line Therapy for Advanced Merkel Cell Carcinoma

March 10, 2022

By clique_admin

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC.

March 10, 2022

By clique_admin

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy

Study of Pembrolizumab Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

March 7, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5′-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

March 7, 2022

By Support_Clique

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC

March 7, 2022

By Tyler Kalist

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA)

Study of Pembrolizumab in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent

March 7, 2022

By Tyler Kalist

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by

Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer

March 7, 2022

By clique_admin

The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility